These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 36496996)

  • 21. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
    Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
    Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
    AlShimemeri S; Fox SH; Visanji NP
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):131-144. PubMed ID: 32366130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment and future prospects of dopa-induced dyskinesias.
    Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
    Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.
    Santos-García D; de Deus T; Cores C; Feal Painceiras MJ; Íñiguez Alvarado MC; Samaniego LB; López Maside A; Jesús S; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández-Vara J; Cabo López I; López Manzanares L; González-Aramburu I; Ávila A; Gómez-Mayordomo V; Nogueira V; Dotor García-Soto J; Borrué-Fernández C; Solano B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Mendoza Z; Pareés I; Sánchez Alonso P; Alonso Losada MG; López-Ariztegui N; Gastón I; Kulisevsky J; Seijo M; Valero C; Alonso Redondo R; Buongiorno MT; Ordás C; Menéndez-González M; McAfee D; Martinez-Martin P; Mir P;
    Mov Disord Clin Pract; 2024 Jul; 11(7):830-849. PubMed ID: 38747234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging drugs for levodopa-induced dyskinesia.
    Al Dakheel A; Beaulieu-Boire I; Fox SH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonism of metabotropic glutamate receptor type 5 prevents levodopa-induced dyskinesia development in a male rat model of Parkinson's disease: Electrophysiological evidence.
    Kamo H; Iwamuro H; Nakamura R; Nojiri S; Okuzumi A; Ogawa T; Nakajima A; Hattori N; Shimo Y
    J Neurosci Res; 2024 Mar; 102(3):e25302. PubMed ID: 38515319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson's disease.
    Yoo HS; Lee EC; Chung SJ; Ye BS; Sohn YH; Seong JK; Lee PH
    Sci Rep; 2022 Jul; 12(1):12631. PubMed ID: 35879381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
    Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
    Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
    Koch G
    Restor Neurol Neurosci; 2010; 28(4):561-8. PubMed ID: 20714078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.
    Jourdain VA; Tang CC; Holtbernd F; Dresel C; Choi YY; Ma Y; Dhawan V; Eidelberg D
    JCI Insight; 2016 Sep; 1(15):e86615. PubMed ID: 27699242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
    Chen X; Wang Y; Wu H; Cheng C; Le W
    Neurol Sci; 2020 Aug; 41(8):2055-2065. PubMed ID: 32185625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
    Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
    CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.